Form Type: 4

SEC EDGAR Link
Acccession Number:0000921895-19-001804
Date:2019-06-10
Issuer: CONCERT PHARMACEUTICALS, INC. (CNCE)
Original Submission Date:

Reporting Person:

BVF PARTNERS L P/IL
44 MONTGOMERY ST.
40TH FLOOR SAN FRANCISCO, CA 94104

Reporting Person:

BIOTECHNOLOGY VALUE FUND L P
44 MONTGOMERY STREET
40TH FL SAN FRANCISCO, CA 94104

Reporting Person:

BIOTECHNOLOGY VALUE FUND II LP
44 MONTGOMERY STREET
40TH FL SAN FRANCISCO, CA 94104

Reporting Person:

BIOTECHNOLOGY VALUE TRADING FUND OS LP
P.O. BOX 309 UGLAND HOUSE
GRAND CAYMAN, E9 KY1-1104

Reporting Person:

BVF PARTNERS OS LTD.
P.O. BOX 309 UGLAND HOUSE
GRAND CAYMAN, E9 KY1-1104

Reporting Person:

BVF INC/IL
44 MONTGOMERY STREET
40TH FL SAN FRANCISCO, CA 94104

Reporting Person:

LAMPERT MARK N
44 MONTGOMERY STREET
40TH FL SAN FRANCISCO, CA 94104

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK, $0.001 PAR VALUE 2019-06-10 S 198,256 d $10.70 1,178,904 f2 direct
COMMON STOCK, $0.001 PAR VALUE 2019-06-10 S 158,583 d $10.70 952,859 f3 direct
COMMON STOCK, $0.001 PAR VALUE 2019-06-10 S 29,450 d $10.70 169,589 f4 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 this form 4 is filed jointly by biotechnology value fund, l.p. ("bvf"), biotechnology value fund ii, l.p. ("bvf2"), biotechnology value trading fund os lp ("trading fund os"), bvf partners os ltd. ("partners os"), bvf partners l.p. ("partners"), bvf inc. and mark n. lampert (collectively, the "reporting persons"). each of the reporting persons is a member of a section 13(d) group. each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
f2 securities owned directly by bvf. as the general partner of bvf, partners may be deemed to beneficially own the securities owned directly by bvf. as the investment adviser and general partner of partners, bvf inc. may be deemed to beneficially own the securities owned directly by bvf. as a director and officer of bvf inc., mr. lampert may be deemed to beneficially own the securities owned directly by bvf.
f3 securities owned directly by bvf2. as the general partner of bvf2, partners may be deemed to beneficially own the securities owned directly by bvf2. as the investment adviser and general partner of partners, bvf inc. may be deemed to beneficially own the securities owned directly by bvf2. as a director and officer of bvf inc., mr. lampert may be deemed to beneficially own the securities owned directly by bvf2.
f4 securities owned directly by trading fund os. as the general partner of trading fund os, partners os may be deemed to beneficially own the securities owned directly by trading fund os. as the investment manager of trading fund os and the sole member of partners os, partners may be deemed to beneficially own the securities owned directly by trading fund os. as the investment adviser and general partner of partners, bvf inc. may be deemed to beneficially own the securities owned directly by trading fund os. as a director and officer of bvf inc., mr. lampert may be deemed to beneficially own the securities owned directly by trading fund os.

Elevate your investments